Sas 9.1.3 statistical software

Descriptive analyses were performed to summarize the participants’ backgrounds and psychological measurement scores. Firstly, logistic regression analysis was performed to obtain Odds ratio of difference in attendance rates among two control groups. After confirming that there was no significant difference, we pooled one control, and multiple logistic regression analysis with the control serving as the reference group was performed to determine if FOBT uptake differed among the tailored-matched message condition, the unmatched-message condition, and the controls during a follow-up period. We also analyzed the cost-effectiveness of the interventions by dividing the cost by the uptake in the number of FOBT. All analyses were based on intention-to-treat, and were performed using SAS 9.1.3 statistical software by an epidemiologist in authors (YI).

Taking time of temperature recovery as clinical main efficacy indicator, we calculate two groups’ sample size using mean superiority test formula. According to data of efficacy evaluation about adult influenza treating with RDN and Oseltamivir in the early stage, the per protocol set (PPS) of time of temperature recovery comes: Oseltamivir is 46.50 ± 1.74(h) and RDN is 30.47 ± 1.69(h); so that δ for 15.35 h, 100 participants will be required for each group, and 200 is the total. If the 20% dropout rate is considered, 240 cases were planned to be observed. We adopt the method of center stratified block randomization in trial: there is 10 centers, 4 segments, each center has 24 cases and each group has 12 cases.
Randomization will be used for patient allocation [22 (link)]. The randomization will be performed by an independent statistician. The random numbers are divided into two groups sequentially: experimental group and control group. SAS 9.1.3 statistical software will be used for seed number, and randomized grouping tables will be generated for the 240 patients receiving treatment. During the trial, the investigator will be able to obtain the randomized number and drug number of each patient from the designated central randomized platform. All random numbers grouped are sent to each trial center and corresponding treatment kits are provided.